Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

IMADEDDINE TABBARA

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1184794414
CMS profile
425581
Location
WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$341,752.81

235 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Celgene Corporation $92,447.78 68
Takeda Pharmaceuticals U.S.A., Inc. $80,071.97 47
Janssen Biotech, Inc. $39,271.98 22
Amgen Inc. $37,948.51 32
AbbVie, Inc. $18,248.34 10
Genentech USA, Inc. $17,609.05 14
Pharmacyclics LLC, An AbbVie Company $17,112.57 17
E.R. Squibb & Sons, L.L.C. $14,475.60 8
Verastem, Inc. $11,590.52 5
JAZZ PHARMACEUTICALS INC. $7,441.58 9
Rigel Pharmaceuticals, Inc. $3,534.91 2
Astellas Pharma US Inc $2,000.00 1

Page 2 of 5; records 51–100 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

IMADEDDINE TABBARA

NPI 1184794414 · CMS profile ID 425581

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

WASHINGTON, DC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1184794414?year=2019&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
IMADEDDINE TABBARA, NPI 1184794414, CMS profile ID 425581. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1184794414?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). IMADEDDINE TABBARA, NPI 1184794414, CMS profile ID 425581. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1184794414?year=2019&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
IMADEDDINE TABBARA, NPI 1184794414, CMS profile ID 425581, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 235 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1184794414?year=2019&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

235 matching records · $341,752.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 235 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 235.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Takeda Pharmaceuticals U.S.A., Inc. $3,300.0008/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697375001 CMS
Takeda Pharmaceuticals U.S.A., Inc. $121.8408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697380665 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,090.1508/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697374483 CMS
Verastem, Inc. $5,280.0008/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699801925 CMS
Amgen Inc. $90.0008/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405719 CMS
Amgen Inc. $410.2508/14/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405741 CMS
Takeda Pharmaceuticals U.S.A., Inc. $4,620.0008/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697374479 CMS
Takeda Pharmaceuticals U.S.A., Inc. $65.6208/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697380225 CMS
Celgene Corporation $1,007.0008/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672931945 CMS
Celgene Corporation $271.0708/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672933155 CMS
Celgene Corporation $6,375.0008/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672961259 CMS
Celgene Corporation $606.6008/12/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672962661 CMS
Amgen Inc. $101.8308/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405721 CMS
Amgen Inc. $624.1008/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405739 CMS
Genentech USA, Inc. $542.3108/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681358353 CMS
Genentech USA, Inc. $120.9008/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681363903 CMS
Genentech USA, Inc. $4,160.0008/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681365885 CMS
Pharmacyclics LLC, An AbbVie Company $750.0008/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709515 CMS
Takeda Pharmaceuticals U.S.A., Inc. $610.5008/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376923 CMS
JAZZ PHARMACEUTICALS INC. $357.8808/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684185999 CMS
Celgene Corporation $139.5608/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672936467 CMS
Janssen Biotech, Inc. $3,300.0007/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743079 CMS
Janssen Biotech, Inc. $414.3007/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743071 CMS
Janssen Biotech, Inc. $109.1907/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743075 CMS
Janssen Biotech, Inc. $3,300.0007/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743069 CMS
Celgene Corporation $119.5307/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672921429 CMS
Celgene Corporation $1,828.3707/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672934401 CMS
Celgene Corporation $5,625.0007/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672963349 CMS
JAZZ PHARMACEUTICALS INC. $306.0007/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684193617 CMS
JAZZ PHARMACEUTICALS INC. $394.3707/23/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684193619 CMS
Pharmacyclics LLC, An AbbVie Company $2,000.0007/23/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665706389 CMS
Janssen Biotech, Inc. $408.3007/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743061 CMS
Janssen Biotech, Inc. $80.6207/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658743065 CMS
Pharmacyclics LLC, An AbbVie Company $1,300.0007/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 665709329 CMS
Takeda Pharmaceuticals U.S.A., Inc. $3,300.0007/17/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376907 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.9207/17/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697379485 CMS
Takeda Pharmaceuticals U.S.A., Inc. $660.0007/16/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376019 CMS
Takeda Pharmaceuticals U.S.A., Inc. $369.5507/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376941 CMS
Takeda Pharmaceuticals U.S.A., Inc. $424.4507/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697376775 CMS
AbbVie, Inc. $2,750.0007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648126855 CMS
JAZZ PHARMACEUTICALS INC. $2,375.0007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684189139 CMS
Amgen Inc. $3,500.0007/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405691 CMS
Amgen Inc. $583.0007/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405694 CMS
AbbVie, Inc. $109.7506/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 648126857 CMS
Amgen Inc. $1,110.9006/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 662405697 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1,320.0006/28/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697375125 CMS
Genentech USA, Inc. $2,600.0006/27/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681239531 CMS
Genentech USA, Inc. $387.0406/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681265967 CMS
Genentech USA, Inc. $86.6906/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681292793 CMS
E.R. Squibb & Sons, L.L.C. $4,125.0006/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651298087 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $341,752.81 235
PY2020 $149,212.74 103
PY2021 $137,930.38 83
PY2022 $245,126.92 136
PY2023 $149,987.03 109
PY2024 $153,604.31 129
PY2025 $49,585.66 130

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $112,036.36 21
PY2024 Principal investigator $29,229.36 6
PY2023 Principal investigator $42,829.91 6
PY2022 Principal investigator $105,478.22 2
PY2021 Principal investigator $85,803.21 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 BeOne Medicines USA, Inc. $1,440.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329711
Principal investigator 1 BeOne Medicines USA, Inc. $934.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329713
Principal investigator 1 BeOne Medicines USA, Inc. $1,000.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329715
Principal investigator 1 BeOne Medicines USA, Inc. $1,680.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329717
Principal investigator 1 BeOne Medicines USA, Inc. $1,680.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329719
Principal investigator 1 BeOne Medicines USA, Inc. $1,680.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329721
Principal investigator 1 BeOne Medicines USA, Inc. $1,200.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329723
Principal investigator 1 BeOne Medicines USA, Inc. $1,440.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329725
Principal investigator 1 BeOne Medicines USA, Inc. $2,500.00 12/23/2025 Non-covered Recipient Entity
Velocity Clinical Research - Durham
A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma No dispute reported 06/30/2026 1190329727
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,100.00 12/18/2025 Non-covered Recipient Entity
Anne Arundel Health System Research Institute, Incorporated
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235998999
Principal investigator 1 Janssen Research & Development, LLC $12,600.00 10/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175414565
Principal investigator 1 Janssen Research & Development, LLC $6,538.00 10/16/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide No dispute reported 06/30/2026 1175414571
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175414467
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175414473
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175414542
Principal investigator 1 Janssen Research & Development, LLC $2,000.00 07/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175414577
Principal investigator 1 BeOne Medicines Ltd. $2,500.00 05/30/2025 Non-covered Recipient Entity
Luminis Health Anne Arundel Medical Center
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell Lymphoma No dispute reported 06/30/2026 1190326985
Principal investigator 1 Celgene Corporation $24,868.00 05/28/2025 Non-covered Recipient Entity
Anne Arundel Health System Research Institute, Incorporated
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1222305330
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,860.00 05/14/2025 Non-covered Recipient Entity
LUMINIS HEALTH
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy ADRIATIC No dispute reported 06/30/2026 1185542796
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16.36 04/21/2025 Non-covered Recipient Entity
Anne Arundel Medical Center
A PHASE 3, TWO-STAGE, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY COMPARING CC-92480 (BMS-986348), CARFILZOMIB AND DEXAMETHASONE (480Kd) VERSUS CARFILZOMIB AND DEXAMETHASONE (Kd) IN PARTICIPANTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM). No dispute reported 06/30/2026 1235998997
Principal investigator 1 Janssen Research & Development, LLC $23,000.00 03/03/2025 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Borte No dispute reported 06/30/2026 1175414480